Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.37−0.01 (-1.40%)
Close on Nov 18, 2026Market cap $1.27MP/E –Yield –
Scinai Immunotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Scinai Immunotherapeutics's R&D Expenses for the twelve months ending Dec 31, 2021 was $3.25M. For fiscal 2025 it was $2.37M, down 57.2% from the year before. The highest annual figure on record is $16.01M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.37M | -57.2% |
| FY2024 | Dec 31, 2024 | $5.53M | +6.2% |
| FY2023 | Dec 31, 2023 | $5.21M | -9.6% |
| FY2022 | Dec 31, 2022 | $5.77M | +77.4% |
| FY2021 | Dec 31, 2021 | $3.25M | -79.7% |
| FY2020 | Dec 31, 2020 | $16.01M | +195.6% |
| FY2017 | Dec 31, 2017 | $5.42M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | $1.45M | +23.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.00M | – |
| Q2 FY2022 | Jun 30, 2022 | $1.97M | – |
| Q1 FY2022 | Mar 31, 2022 | $1.16M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.18M | – |
See a number that looks wrong?